CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Revenues:
License and milestone fees	$ 10,077	$ 5,078	$ 26,839	$ 52,729
Royalty revenue		5,099	195	13,890
Non-cash royalty revenue related to the sale of future royalties	7,380		19,355
Research and development support	1,059	532	2,679	2,140
Clinical materials revenue	1,198	718	3,526	4,171
Total revenues	19,714	11,427	52,594	72,930
Operating Expenses:
Research and development	36,094	25,666	109,425	81,331
General and administrative	11,235	7,000	27,618	20,967
Total operating expenses	47,329	32,666	137,043	102,298
(Loss) income from operations	(27,615)	(21,239)	(84,449)	(29,368)
Investment income, net	108	14	219	36
Non-cash interest expense on liability related to the sale of future royalties	(4,972)		(15,174)
Other income (expense), net	551	(393)	509	(933)
Net (loss) income	$ (31,928)	$ (21,618)	$ (98,895)	$ (30,265)
Basic and diluted net (loss) income per common share (in dollars per share)	$ (0.37)	$ (0.25)	$ (1.14)	$ (0.35)
Basic weighted average common shares outstanding (in shares)	87,035	86,080	86,948	85,962
Total comprehensive (loss) income	$ (31,928)	$ (21,618)	$ (98,895)	$ (30,265)